Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronnie T Poon

Showing results (81-90 of 89) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 89 results.
The Journal of Biological Chemistry|July 9, 2011
DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survivalJohn M Luk, Julja Burchard, Chunsheng Zhang, et al.
The Lancet. Oncology|September 13, 2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialJordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, et al.
The New England Journal of Medicine|June 14, 2013
Oncofetal gene SALL4 in aggressive hepatocellular carcinomaKol Jia Yong, Chong Gao, Joline S J Lim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 22, 2013
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)Joong-Won Park, Deepak Amarapurkar, Yee Chao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJosep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2014
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinomaDarrell R Borger, Lipika Goyal, Thomas Yau, et al.
Nature Genetics|May 29, 2012
Genome-wide survey of recurrent HBV integration in hepatocellular carcinomaWing-Kin Sung, Hancheng Zheng, Shuyu Li, et al.
Annals of Surgery|November 17, 2009
The international position on laparoscopic liver surgery: The Louisville Statement, 2008Joseph F Buell, Daniel Cherqui, David A Geller, et al.
Genome Research|June 22, 2013
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaZhengyan Kan, Hancheng Zheng, Xiao Liu, et al.
Pageof 9

Showing results (81-90 of 89) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 89 results.
The Journal of Biological Chemistry|July 9, 2011
DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with poor survivalJohn M Luk, Julja Burchard, Chunsheng Zhang, et al.
The Lancet. Oncology|September 13, 2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialJordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, et al.
The New England Journal of Medicine|June 14, 2013
Oncofetal gene SALL4 in aggressive hepatocellular carcinomaKol Jia Yong, Chong Gao, Joline S J Lim, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 22, 2013
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)Joong-Won Park, Deepak Amarapurkar, Yee Chao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS studyJosep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2014
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinomaDarrell R Borger, Lipika Goyal, Thomas Yau, et al.
Nature Genetics|May 29, 2012
Genome-wide survey of recurrent HBV integration in hepatocellular carcinomaWing-Kin Sung, Hancheng Zheng, Shuyu Li, et al.
Annals of Surgery|November 17, 2009
The international position on laparoscopic liver surgery: The Louisville Statement, 2008Joseph F Buell, Daniel Cherqui, David A Geller, et al.
Genome Research|June 22, 2013
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinomaZhengyan Kan, Hancheng Zheng, Xiao Liu, et al.
Pageof 9